Bill Enright
Chief Executive Officer Barinthus Biotherapeutics
William “Bill” Enright is a seasoned biotech executive with more than thirty years of experience in building and financing both privately held and publicly held companies. Bill spent more than ten years at Altimmune (NASDAQ: ALT) as a Director, President & CEO, moving multiple programs into clinical testing, completing several acquisitions and eventually taking the company public. Prior to joining Altimmune, Bill spent six years with GenVec, Inc. (acquired by Intrexon) with increasing responsibilities, which included a role as Head of Business Development. He currently serves on the Board of Directors of Gravitas Therapeutics, Inc. Bill brings a breadth of experiences in a variety of positions within the life science/biotech industry, including time as a consultant, a bench scientist and 12 years with Life Technologies, Inc. (acquired by Thermo-Fisher), working in various senior level licensing, business management, manufacturing and research roles.
Seminars
- Implementing standardized methodologies to create consistent and reliable potency assays for tolerance therapies, ensuring product quality and regulatory compliance
- Establishing clear acceptance criteria and validation protocols for potency assays, moving beyond theoretical frameworks to provide actionable guidelines for clinical and commercial applications
- Utilizing mechanistic insights from potency assays to predict therapeutic outcomes, guiding dose optimization and patient stratification for improved clinical efficacy
